Your browser doesn't support javascript.
loading
Interleukin-36 Cytokines in Infectious and Non-Infectious Lung Diseases.
Peñaloza, Hernán F; van der Geest, Rick; Ybe, Joel A; Standiford, Theodore J; Lee, Janet S.
Afiliación
  • Peñaloza HF; Acute Lung Injury Center of Excellence, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
  • van der Geest R; Acute Lung Injury Center of Excellence, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
  • Ybe JA; Department of Environmental and Occupational Health, School of Public Health, Indiana University, Bloomington, IN, United States.
  • Standiford TJ; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, United States.
  • Lee JS; Acute Lung Injury Center of Excellence, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Front Immunol ; 12: 754702, 2021.
Article en En | MEDLINE | ID: mdl-34887860
ABSTRACT
The IL-36 family of cytokines were identified in the early 2000's as a new subfamily of the IL-1 cytokine family, and since then, the role of IL-36 cytokines during various inflammatory processes has been characterized. While most of the research has focused on the role of these cytokines in autoimmune skin diseases such as psoriasis and dermatitis, recent studies have also shown the importance of IL-36 cytokines in the lung inflammatory response during infectious and non-infectious diseases. In this review, we discuss the biology of IL-36 cytokines in terms of how they are produced and activated, as well as their effects on myeloid and lymphoid cells during inflammation. We also discuss the role of these cytokines during lung infectious diseases caused by bacteria and influenza virus, as well as other inflammatory conditions in the lungs such as allergic asthma, lung fibrosis, chronic obstructive pulmonary disease, cystic fibrosis and cancer. Finally, we discuss the current therapeutic advances that target the IL-36 pathway and the possibility to extend these tools to treat lung inflammatory diseases.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Interleucina-1 / Inflamación / Enfermedades Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Interleucina-1 / Inflamación / Enfermedades Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos